Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Arizona Brand Exception Coverage | Open…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield of ArizonaPolicy N/A

    Brand Over Generic Medication Exception

    Customize your policy alerts

    Sign up for all blue cross blue shield - arizona policy alerts

    Know when blue cross blue shield - arizona releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Pharmacy coverage guideline for medical necessity and prior authorization of brand medications requested instead of generic equivalents for Commercial and Marketplace members; excludes Federal Employee Program, Medicare Advantage, Medicaid, and out-of-state Blue Cross and Blue Shield members.

    Policy Summary
    PayerBlue Cross Blue Shield of Arizona
    PolicyBrand Over Generic Medication Exception
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a fully completed prior authorization request with chart notes, laboratory workup, supporting documentation, and the prescribing provider’s signature.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Commercial/MarketplaceApplicable plan types
    3 monthsGeneric trial duration
    3Alternative manufacturers
    CTCAE ≥3Adverse reaction threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 months
    Initial approval duration

    Coverage Criteria

    Initial Therapy — Prescriber, Indication, and Age

    Covered for initial therapy when all of the following are met:

    ALL of the following

    • Prescribed by a physician specializing in the diagnosis or in consultation with a physician in the clinically appropriate specialty
    • Diagnosis is consistent with the FDA-approved product labeling
    • Age is consistent with the FDA-approved product labeling

    Baseline Clinical Evaluation

    For initial therapy, all of the following baseline clinical evaluation requirements must be met:

    ALL of the following

    • Requested dosage, duration of use, and indication are consistent with FDA-approved product labeling
    • ONE of the following from the generic medication

      • Therapeutic drug failure: expected drug effects did not occur after at least three months of use of the generic medication at the usual therapeutic dose>= 3 months
      • Significant adverse drug reaction, including intolerance or an immune-related allergic reaction, rated Common Toxicity Criteria for Adverse Events (CTCAE) Grade 3 or higher and determined to be probably or definitely caused by the generic medicationCTCAE Grade >= 3

    Brand Specific Criteria

    For requests based on a significant adverse event, all of the following must be met:

    ALL of the following

    • Tried an alternative generic medication from three different manufacturers or labelers, if available, and the significant adverse event recurred3 manufacturers or labelers, if available
    • Prescriber submitted a report of the adverse reaction using MedWatch Form FDA 3500 — Voluntary Reporting; a copy of the report is required

      MedWatch Form FDA 3500: https://www.fda.gov/media/76299/download

    Safety

    All applicable safety requirements must be met:

    ALL of the following

    • No FDA-labeled contraindications
    • No concomitant drug use that may cause severe adverse reactions or significant drug interactions requiring discontinuation

    Additional Requirements

    The request must meet the following benefit requirement:

    No conflicting benefit exclusions

    Continuation Therapy Criteria

    Continuation therapy is covered when all applicable renewal requirements are met:

    ALL of the following

    • Continues to be seen by a physician specializing in the diagnosis or in consultation with a physician in the clinically appropriate specialty
    • Condition has responded while on therapy, defined as no evidence of disease progression or unacceptable toxicity
    • Adherence to the prescribed therapy regimen has been documented
    • Brand-specific requirements, when applicable for a significant adverse event

      • Provider submitted individual-specific clinical justification explaining why an A-rated generic medication cannot be used

    Coverage is subject to applicable benefit plan terms and exclusions. Requests are not covered when a conflicting benefit exclusion applies.

    Coverage is not provided when an FDA-labeled contraindication is present, or when concomitant drug use may cause severe adverse reactions or significant drug interactions requiring discontinuation.

    Initial Therapy — Consolidated Coverage Logic

    Initial therapy coverage requires all applicable prescriber, labeling, clinical, safety, brand-specific, and benefit requirements below:

    ALL applicable initial therapy requirements

    • Prescribed by a physician specializing in the diagnosis or in consultation with a physician in the clinically appropriate specialty
    • Diagnosis, requested dosage, duration of use, and age are consistent with FDA-approved product labeling
    • ONE of the following documented qualifying experiences with the generic medication

      • Therapeutic drug failure: expected drug effects did not occur after at least three months of use at the usual therapeutic dose>= 3 months
      • Significant adverse drug reaction, including intolerance or an immune-related allergic reaction, rated CTCAE Grade 3 or higher and determined to be probably or definitely caused by the generic medication

    Key Thresholds and Requirements

    Generic Therapeutic Failure
    Therapeutic failure durationAt least three months of use of the generic medication at the usual therapeutic dose
    Qualifying outcomeExpected drug effects did not occur after the required therapeutic trial
    ApplicationSupports a brand medication exception when the requested dosage, duration, and indication also match FDA-approved product labeling
    Generic-Related Adverse Reaction
    Minimum severityCTCAE Grade 3 or higher
    Qualifying reactionsIntolerance or an immune-related allergic reaction caused by the generic medication
    Causation standard

    Provider Actions and Documentation

    Prior Authorization

    Submit the Prior Authorization Request

    Submit a complete prior authorization request for the brand-over-generic exception. The prescribing provider must sign the form and submit it to BCBSAZ Pharmacy Management by fax at (602) 864-3126 or email at Pharmacyprecert@azblue.com.

    • Use the request form available through www.azblue.com/pharmacy.
    • Do not use patient samples as evidence of an initial course, continuation, or adequate trial and failure.
    Documentation Required

    Brand Exception Clinical Justification

    Provide individualized clinical justification explaining why an A-rated generic medication cannot be used for this member. Document the relevant generic medication trials, outcomes, and clinical rationale supporting brand coverage.

    • Include the diagnosis, requested dosage, duration, and indication.
    • Explain the member-specific reason the A-rated generic is inappropriate or cannot be used.

    Background

    The guideline distinguishes a brand-name medication from an FDA-rated therapeutically equivalent generic product. An A-rated generic has demonstrated therapeutic equivalence to the corresponding brand product and is generally used before a brand exception is considered. A brand exception may be supported when the member demonstrates therapeutic failure after at least three months of generic use at the usual therapeutic dose or experiences a significant generic-related adverse reaction rated CTCAE Grade 3 or higher. For an adverse-reaction exception, the provider must document trials of an alternative generic from three different manufacturers or labelers, when available, recurrence of the reaction, individualized clinical justification, and the required MedWatch Form FDA 3500 report.

    Definitions

    Generic Drug
    Active ingredientThe same active ingredient or ingredients as the marketed brand-name drug
    Product characteristicsThe same dosage form, strength, route of administration, quality, performance characteristics, and intended use
    EquivalenceFDA-demonstrated bioequivalence and therapeutic equivalence, meaning the generic works in the same way and provides the same clinical benefit as the brand-name medicine
    A-Rated Product
    FDA designationAn A-rated product is a generic product designated by the FDA as therapeutically equivalent to the corresponding innovator or brand product
    Expected performanceComparable absorption and blood levels to the brand-name product

    Initial Therapy Criteria

    Initial Therapy

    Covered for an initial brand exception when all applicable medical-necessity requirements are satisfied:

    Initial brand exception

    • Prescriber and labeling requirements: The request is prescribed by a physician specializing in the diagnosis or by a physician in consultation with a physician in the clinically appropriate specialty; the diagnosis and member age are consistent with FDA-approved product labeling; and the requested dosage, duration of use, and indication are consistent with FDA-approved product labeling.
    • ONE qualifying generic outcome

      • Therapeutic drug failure: Expected drug effects did not occur after at least three months of use of the generic medication at the usual therapeutic dose.at least 3 months

    Continuation Criteria

    Continuation Therapy Renewal

    Continuation therapy requires renewal review:

    Renewal review: The continuation request is submitted for renewal review.

    Manufacturer assistance, including coupons and samples, is not considered for continuation of therapy.

    Continuation of Brand Exception

    Continuation of the brand exception requires all applicable criteria to be satisfied:

    Brand-over-generic continuation: The member continues to be seen by a physician specializing in or consulting with a physician in the clinically appropriate specialty; the condition has responded while on therapy, with no evidence of disease progression or unacceptable toxicity; adherence to the prescribed therapy regimen is documented; no concomitant drug use may cause severe adverse reactions or significant drug interactions requiring discontinuation; the provider submitted individual clinical justification for why an A-rated generic medication cannot be used; when available, an alternative generic medication from three different manufacturers or labelers was tried and the significant adverse event recurred; the prescriber submitted a MedWatch Form FDA 3500 report with a copy of the report; and chart notes, supporting clinical documentation showing improvement in the indication, and laboratory values confirming safe use are submitted.

    Step Therapy

    StepRequirementDetails
    1Try the generic medication before requesting the brand medication exception.The member must demonstrate therapeutic failure after at least three months of generic use at the usual therapeutic dose, or a significant generic-related adverse reaction rated CTCAE Grade 3 or higher.
    StepRequirementDetails
    1Try an alternative generic medication from three different manufacturers or labelers, when available, before requesting the brand medication exception.For a significant adverse-event request, the event must recur after the alternative generic trials.
    Policy Summary
    PayerBlue Cross Blue Shield of Arizona
    PolicyBrand Over Generic Medication Exception
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a fully completed prior authorization request with chart notes, laboratory workup, supporting documentation, and the prescribing provider’s signature.
    SourceLink
    On This Page
    Coverage CriteriaKey Thresholds and RequirementsProvider Actions and DocumentationBackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaStep Therapy
    Tried an alternative generic medication from three different manufacturers or labelers, if available, and the significant adverse event recurred3 manufacturers or labelers, if available
  1. Prescriber submitted a report of the adverse reaction using MedWatch Form FDA 3500 — Voluntary Reporting; a copy of the report is required

    MedWatch Form FDA 3500: https://www.fda.gov/media/76299/download

  2. No concomitant drug use that may cause severe adverse reactions or significant drug interactions requiring discontinuation
  3. Required supporting documentation

    • Chart notes
    • Supporting clinical documentation with evidence of improvement in the given indication
    • Laboratory values that confirm safe use based on the criteria above
  4. Continuation approval duration is 12 months or the end of the plan year12 months or end of plan year
  5. CTCAE Grade >= 3
  6. When coverage is based on a significant adverse event

    • Tried an alternative generic medication from three different manufacturers or labelers, if available, and the significant adverse event recurred3 manufacturers or labelers, if available
    • Prescriber submitted a MedWatch Form FDA 3500 adverse-reaction report; a copy is required

      https://www.fda.gov/media/76299/download

  7. No FDA-labeled contraindications
  8. No concomitant drug use that may cause severe adverse reactions or significant drug interactions requiring discontinuation
  9. No conflicting benefit exclusions
  10. The reaction must be determined to be probably or definitely caused by the generic medication
    Alternative Generic Manufacturers or Labelers
    Required trialAn alternative generic medication must be tried from three different manufacturers or labelers, if available
    Applicable requestsRequests based on a significant adverse event
    Additional conditionThe significant adverse event must recur after the alternative generic trials
    Documentation Required

    Report Significant Generic Adverse Reactions

    For a significant adverse reaction to a generic medication, submit the prescriber’s MedWatch Form FDA 3500—Voluntary Reporting, and include a copy with the coverage request.

    • Report reactions that are CTCAE Grade 3 or higher and probably or definitely caused by the generic medication.
    • MedWatch form: https://www.fda.gov/media/76299/download
    Step Therapy

    Generic-First Requirement

    Meet the generic-first requirement before requesting brand coverage. Document either therapeutic failure after at least three months at the usual therapeutic dose or a qualifying significant adverse reaction to the generic medication.

    • Therapeutic failure means expected drug effects did not occur.
    • Qualifying intolerance or immune-related allergy must be CTCAE Grade 3 or higher and probably or definitely caused by the generic medication.
    Documentation Required

    Required Request Documentation

    Submit the completed request form with the clinical record needed to evaluate the exception. Incomplete documentation may delay review or result in non-approval.

    • Chart notes
    • Laboratory results or lab workup
    • Supporting clinical documentation
    Documentation Required

    MedWatch Adverse-Event Report

    When coverage is based on recurrent significant adverse events, document trials of an alternative generic from three different manufacturers or labelers, if available, and submit the prescriber’s MedWatch Form FDA 3500 report with the request.

    • Include a copy of the adverse-event report.
    • Document the manufacturer or labeler for each generic trial and the recurrence of the significant adverse event.
    Documentation Required

    Clinical and Laboratory Documentation

    Support continuation or exception requests with evidence that the member has improved on therapy and that use remains safe. Provide clinical documentation and laboratory confirmation where applicable.

    • Chart notes must show evidence of improvement in the treated indication.
    • Laboratory values must confirm safe use under the applicable criteria.
    Documentation Required

    MedWatch Adverse-Reaction Report

    For recurrent significant generic adverse events, the prescriber must submit a voluntary FDA Form 3500 report and provide supporting documentation with the request.

    • The report must address the adverse reaction associated with the generic medication.
    • Include documentation of trials from three different manufacturers or labelers, if available, and recurrence of the event.

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Clinical effectProducts determined to be therapeutically equivalent can be expected to have equivalent clinical effect whether brand name or generic
    Biosimilar
    DefinitionA biological product highly similar to a reference product
    Inactive componentsMinor differences in clinically inactive components may be present
    Clinical differencesThere are no clinically meaningful differences in safety, purity, or potency
    Interchangeable Biological Product
    DefinitionA biological product shown to be biosimilar to a reference product
    Expected resultExpected to produce the same clinical result as the reference product in any given patient
    Switching standardFor products administered more than once, the risk of alternating or switching must not be greater than using the reference product without switching
    Adverse Drug Reaction
    DefinitionA potentially harmful, unintended effect caused by taking a medication
    Severity frameworkThe CTCAE grades reactions on a scale from 1 through 5
    RangeGrade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 has life-threatening consequences; and Grade 5 is death related to the adverse event
    Therapeutic Drug Failure
    DefinitionFailure to accomplish the expected treatment goal because the expected drug effect does not occur
    Treatment requirementThe failure follows prescribed pharmacological treatment using therapeutic doses
    Minimum durationAt least three months of treatment
    MedWatch
    ProgramThe FDA medical product safety reporting program
    Who may reportHealth professionals, patients, and consumers may submit voluntary reports
    Reportable eventsSerious adverse events, product quality problems, product use or medication errors, and suspected therapeutic inequivalence or failure
    Applicable formForm FDA 3500 - Voluntary Reporting
    Adverse Drug Reaction (ADR)
    DefinitionA potentially harmful, unintended effect caused by taking a medication
    Grade 1Mild; asymptomatic or mild symptoms, with no intervention indicated
    Grade 2Moderate; minimal, local, or noninvasive intervention indicated, with limitations in instrumental activities of daily living
    Grade 3Severe or medically significant but not immediately life-threatening; hospitalization, disabling effects, or limits on self-care may occur
    Grades 4-5Grade 4 involves life-threatening consequences requiring urgent intervention; Grade 5 is death related to the adverse event
    Therapeutic Drug Failure
    DefinitionInability to accomplish the goal or goals of treatment because the expected drug effect does not occur
    Treatment basisOccurs after prescribed pharmacological treatment using therapeutic doses
    Required durationAt least 3 months of treatment
    Drug Intolerance
    DefinitionInability to tolerate a known non-immune-mediated adverse effect of a medication
    Labeling requirementThe adverse effect is listed in FDA product labeling
    Use conditionsOccurs with therapeutic dosing and does not depend on prior exposure
    Related termThe reaction may also be described as a drug side effect
    Drug Allergy or Drug Allergic Reaction
    DefinitionAn immune-mediated reaction caused by taking a medication
    Distinction from intoleranceA drug allergy is not the same as a drug intolerance or side effect
    Distinction from toxicityA drug allergy differs from a toxic reaction caused by an overdose of medication
    Significant adverse drug reaction: The generic medication caused an intolerance or immune-related allergic reaction rated CTCAE Grade 3 or higher, and the reaction was determined to be probably or definitely caused by the generic medication.CTCAE Grade 3 or higher
  11. Applicable brand-specific requirements: For a request based on a significant adverse event, an alternative generic medication from three different manufacturers or labelers was tried, if available; the significant adverse event recurred; and the prescriber submitted a MedWatch Form FDA 3500 report with a copy of the report.3 manufacturers or labelers, if available
  12. Safety requirements: There are no FDA-labeled contraindications, and no concomitant drug use may cause severe adverse reactions or significant drug interactions requiring discontinuation.
  13. Benefit requirement: There are no conflicting benefit exclusions.
  14. 3 manufacturers or labelers, if available

    Approval duration is 12 months or the end of the plan year.